KOD
NASDAQKodiak Sciences Inc
News · 26 weeks35+100%
2026-04-192026-10-11
Mix1790d
- Other8(47%)
- Insider4(24%)
- SEC Filings3(18%)
- Analyst1(6%)
- Offering1(6%)
Latest news
25 items- PRKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026.Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).PALO ALTO, Calif., Oct. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kodiak Sciences IncSCHEDULE 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
- INSIDERDirector Baker Bros. Advisors Lp bought $63,397,609 worth of shares (715,592 units at $88.59) (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERDirector Baker Bros. Advisors Lp bought $34,963,077 worth of shares (418,323 units at $83.58) (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERDirector Baker Bros. Advisors Lp bought $58,625,708 worth of shares (807,840 units at $72.57) (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERChairman and CEO Perlroth Victor exercised 1,280,524 shares at a strike of $4.20, increasing direct ownership by 53% to 3,676,062 units (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- PR4 Explosive Stories Enter the Investor SpotlightDENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), DataMeds AI (NASDAQ:MEDS), and KNOREX (NYSEAMERICAN:KNRX) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects. Kodiak Sciences: Five Phase 3 Wins Put Zenkuda on the Regulatory Runway Kodiak Sciences (NASDAQ:KOD) delivered one of the biggest clinical updates in the group. Its pivotal Phase 3 DAYBREAK study produced positive primary-endpoint results for both Zenkuda and tabirafusp-ted in wet age-related macular degeneration. Zenkuda achieved non-inferiority to aflibercept on
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRZenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing, establishing a first-line benchmark in wet age-related macular degeneration (wAMD)Zenkuda multi-indication biologics license application (BLA) planned for the fourth quarter of 2026 to include five positive Phase 3 studies across wAMD, diabetic retinopathy and retinal vein occlusionTabirafusp alfa tedromer (tabirafusp-ted) met the vision primary endpoint (p-value of 0.0036) and anatomical key secondary endpoint (p-value of <0.0001)Post-hoc analyses to identify which treatment naïve
- PRKodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular DegenerationKodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026. The webcast can be accessed at the following link DAYBREAK Topline Results Webcast or from the Events and Presen
- ANALYSTGoldman resumed coverage on Kodiak Sciences with a new price targetGoldman resumed coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $36.00
- SECSEC Form SCHEDULE 13G filed by Kodiak Sciences IncSCHEDULE 13G - Kodiak Sciences Inc. (0001468748) (Subject)
- SECSEC Form 10-Q filed by Kodiak Sciences Inc10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsPALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular Edema Secondary to Inflammation. We comple
- PRKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular EdemaPhase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's ABC® Platform and designed to potently inhibit two complementary pathways implicated in retinal vascular disease
- PRKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 releaseCompletion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation ("MESI"). Kodiak also reaffirmed its plan to release the topline data from Pivotal
- INSIDERSEC Form 4 filed by Chief Financial Officer Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Chairman and CEO Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Yang Taiyin4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Profusek Robert4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Levy Richard S4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Dahiyat Bassil I4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Bancroft Charles A4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - Kodiak Sciences Inc. (0001468748) (Issuer)
KOD FAQ
7 questionsWhat does Kodiak Sciences Inc do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific...Where does KOD stock trade?
Kodiak Sciences Inc (KOD) is listed on NASDAQ.What sector and industry is KOD in?
Kodiak Sciences Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kodiak Sciences Inc go public?
Kodiak Sciences Inc (KOD) completed its IPO in 2018.What are analysts saying about KOD?
Kodiak Sciences Inc has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $3600.00 price target on 2026-09-24. Recent price targets range from $1500.00 to $3600.00.What companies are similar to KOD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KOD side-by-side with any of them on Quantisnow.How can I track KOD on Quantisnow?
Quantisnow aggregates Kodiak Sciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KOD to receive live email and push alerts on every new disclosure.